To validate the predictive power of the VAP proteomic signature, we biochemically assessed the levels of S100A8, LTF and ACTN1 in the BALF of a separate group of mechanically ventilated patients with clinical suspicion for VAP (Figure 5). The gene discussed is S100A8; the disease is ventilator-associated pneumonia.